247
Views
2
CrossRef citations to date
0
Altmetric
Review

Advances in cardiac pacing and defibrillation

, &
Pages 429-440 | Received 08 Feb 2017, Accepted 08 May 2017, Published online: 29 May 2017
 

ABSTRACT

Introduction: There have been many evolutionary milestones in cardiac implantable electronic device (CIED) therapy over the past few decades. These advancements have created new  challenges. Right ventricular pacing was the original (late 1950s) breakthrough, however the risk of pacing induced dyssynchrony has become evident. Biventricular pacing provided a viable way to mitigate dyssynchrony, but only benefits certain patients (primarily left bundle branch block and QRS duration ≥150 ms with depressed left ventricular (LV) function).

Areas covered: Recent advances have made His Bundle pacing an option that may provide physiological pacing for a wider patient population. Traditional CIED systems utilize transvenous endocardial leads. Unfortunately, leads have been CIEDs’ weakest link. Lead-related vascular occlusion, infection and malfunction have spurred the need for percutaneous lead extraction, and development of subcutaneous ICDs and leadless pacing. These options are important for individuals with limited vascular access and those at risk for blood borne infection. Subcutaneous ICDs have been proposed as optimal for younger patients. This recommendation is controversial.

Expert commentary: We review recent advances including His bundle pacing, percutaneous lead extraction, leadless pacing and subcutaneous ICDs as well as their potential use in combination. Additional technological evolution promises to make the future of CIEDs exciting.

Declaration of interest

P.S. Sharma has received honoraria from Medtronic. R. Trohman has worked as an advisor for Boston Scientific/Guidant, received research grants from Boston Scientific/Guidant, Medtronic Inc, St Jude Medical, Vitatron, and WyethAyerst/Wyeth Pharmaceuticals, worked as a consultant for Biosense Webster and St Jude Medical and received honoraria from Boston Scientific/Guidant CRM, Medtronic Inc, Daiichi Sankyo and St Jude Medical. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.